Apple v. ITC (23-1553): Federal Circuit Vacates Cardiac Monitoring Patent Ruling
Apple challenged an International Trade Commission determination covering three patents on discordance monitoring and arrhythmia tracking and scoring. After 735 days, the Federal Circuit vacated the ITC’s ruling and remanded for further proceedings, nullifying the lower determination without a final merits resolution.
Federal Circuit wipes ITC slate clean on Apple heart-monitoring patents
Apple, Inc. appealed to the United States Court of Appeals for the Federal Circuit on 3 March 2023, challenging a determination by the International Trade Commission relating to three patents — US9572499B2, US10638941B2, and US10595731B2 — covering discordance monitoring and methods and systems for arrhythmia tracking and scoring. The patents are central to wearable cardiac health monitoring technology, the kind embedded in Apple Watch and similar devices.
On 7 March 2025, the Federal Circuit issued its order vacating the ITC’s determination and remanding the matter. A vacatur means the lower tribunal’s decision is nullified — it carries no legal force going forward. The case now returns to the ITC, which must reconsider the matter consistent with the Federal Circuit’s guidance. Neither side secured a final merits victory; the dispute is effectively reopened at the agency level.
The 735-day appellate duration is consistent with a substantive Federal Circuit review rather than a procedural dismissal, suggesting the court identified meaningful legal error in the ITC’s analysis. The precise grounds for vacatur are embedded in the court’s order but the public docket entry confirms the outcome. What remains unknown from the public record is the specific legal basis — claim construction, obviousness, or domestic industry — that the Federal Circuit found deficient, and how the ITC will resolve the matter on remand.
Filing to Vacated and Remanded in 735 days
735 days — over two years from ITC appeal to Federal Circuit disposition
Federal Circuit vacates ITC: what the remand means for both parties
Vacatur nullifies the ITC determination entirely
When the Federal Circuit vacates a lower tribunal’s decision, that decision is wiped from the record — it has no precedential or binding effect on either party. Unlike a reversal, which substitutes the appellate court’s judgment, a vacatur with remand sends the case back for the lower body to reconsider. The ITC must now re-examine its determination on the three cardiac monitoring patents under whatever corrected legal standard the Federal Circuit prescribed.
Remand to ITC requiredApple gains a second chance — ITC must start over
As appellant, Apple successfully destabilised the ITC’s original determination. The vacatur removes any adverse ruling against Apple that the ITC had issued. On remand, Apple will have the opportunity to re-argue its position before the ITC under the corrected framework. However, this is not a win on the merits — Apple must still prevail at the agency level before securing a final favourable outcome on these cardiac monitoring patents.
No final win yet — remand pendingITC determination vacated — patent holders face renewed uncertainty
The ITC, as appellee, must reconsider its own prior determination. Any party that benefited from the original ITC ruling — including any patent holder whose exclusion order or finding was upheld — now faces renewed uncertainty. The Federal Circuit’s vacatur signals that the ITC’s analytical framework or factual findings were legally deficient. Parties relying on that determination for commercial or enforcement purposes cannot do so while remand proceedings are ongoing.
Prior ITC ruling unenforceableWearable cardiac tech IP landscape remains unsettled
The vacatur preserves uncertainty for the entire wearable health monitoring sector. Three patents covering discordance monitoring and arrhythmia tracking and scoring remain in active dispute at the ITC level. Competitors, licensees, and product teams developing cardiac monitoring features in wearables should treat these patents as live enforcement risks. No design-around or freedom-to-operate conclusion based on the original ITC determination should be relied upon without updated legal analysis.
FTO analysis requiredFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Apple, Inc. | Company | Technology company — appellant challenging ITC ruling on cardiac monitoring patentsSearch in Eureka ↗ |
| Defendant | International Trade Commission | Individual | U.S. International Trade Commission — federal agency whose determination was under appellate reviewSearch in Eureka ↗ |
| Plaintiff counsel | Benjamin Elacqua | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Betty H. Chen | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Plaintiff counsel | E. Joshua Rosenkranz | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Elizabeth Moulton | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Isaac Park | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Kristina McKenna | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Mark S. Davies | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Melanie L. Bostwick | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Michael Ari Amon | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Ruffin B. Cordell | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Zachary Hennessee | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Desmarais LLP | Law Firm | Representing Apple, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Fish & Richardson PC | Law Firm | Representing Apple, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Latham & Watkins LLP | Law Firm | Representing Apple, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Orrick, Herrington & Sutcliffe LLP | Law Firm | Representing Apple, Inc.Search in Eureka ↗ |
| Plaintiff law firm | White & Case LLP | Law Firm | Representing Apple, Inc.Search in Eureka ↗ |
| Defendant counsel | Panyin Hughes Advisor | Attorney | Counsel for International Trade CommissionSearch in Eureka ↗ |
| Defendant counsel | Sidney A. Rosenzweig Advisor | Attorney | Counsel for International Trade CommissionSearch in Eureka ↗ |
| Defendant counsel | Wayne W. Herrington | Attorney | Counsel for International Trade CommissionSearch in Eureka ↗ |
| Defendant law firm | United States International Trade Commission | Law Firm | Representing International Trade CommissionSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘VACATED AND REMANDED’ — is terse but consequential. Vacatur at the appellate level means the ITC’s determination is nullified and given no legal weight. The Federal Circuit applies its own de novo review to legal questions such as claim construction and statutory interpretation, and reviews ITC factual findings for substantial evidence. The use of ‘vacated and remanded’ rather than ‘reversed’ typically signals the appellate court found the lower tribunal’s reasoning legally deficient but declined to substitute its own final judgment, instead directing the ITC to reconsider under a corrected standard. Neither party has achieved a final merits resolution on the three cardiac monitoring patents.
US9572499B2, US10638941B2 & US10595731B2 — Cardiac Monitoring Methods
The three patents at issue — US9572499B2 (application US14/730122), US10638941B2 (application US16/158112), and US10595731B2 (application US16/588201) — cover discordance monitoring and methods and systems for arrhythmia tracking and scoring. These patents sit at the intersection of signal processing and clinical cardiology, covering techniques for detecting and classifying irregular heart rhythms using wearable sensors. The progression of application numbers suggests a family of related inventions filed across multiple continuation or continuation-in-part applications.
For the wearable health technology sector, these patents represent high-value assets. Arrhythmia detection — particularly atrial fibrillation detection — is a commercially differentiated feature in consumer smartwatches and medical-grade wearables, and is subject to increasing regulatory scrutiny and reimbursement interest. A patent portfolio covering discordance monitoring and arrhythmia scoring methods could support both ITC exclusion actions against importers and district court enforcement against domestic competitors. The outcome of the ITC remand will directly affect the enforceability of these claims against any party making, using, or importing arrhythmia monitoring technology.
Should your team run an FTO against US9572499B2 and related patents?
Any organisation developing or importing wearable devices with cardiac monitoring capabilities — including arrhythmia detection, ECG analysis, or heart rate discordance measurement — should treat these three patents as live FTO concerns. The ITC remand means the enforceability question is unresolved, and a remand outcome favouring the patent holder could rapidly trigger exclusion orders or injunctive relief. R&D and product teams building on any of these signal-processing methods need current claim-level clearance analysis.
PatSnap Eureka’s FTO Search Agent can map each independent claim of US9572499B2, US10638941B2, and US10595731B2 against your product architecture, flag prior art that may support design-around arguments, and identify continuation applications still pending in the same family. Given the active ITC remand, monitoring for new claim filings in this patent family is equally critical — Eureka’s portfolio watch tools can alert your team to any prosecution developments in real time.
Run a freedom-to-operate analysis on US9572499B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals involving cardiac monitoring and ITC determinations
Explore Federal Circuit cases involving ITC determinations on wearable health monitoring and medical signal processing patents — the same court and technology domain as Case 23-1553.
What this case signals for the wearable health monitoring IP landscape
A Federal Circuit vacatur of an ITC ruling on cardiac monitoring patents reshapes enforcement risk across the wearable health tech sector.
ITC exclusion orders built on flawed analysis remain vulnerable on appeal
This case illustrates that ITC determinations — even those covering commercially critical patents like arrhythmia monitoring — can be vacated when the Federal Circuit identifies legal error. Companies facing ITC proceedings should anticipate appellate scrutiny of the ITC’s claim construction and domestic industry analysis, both frequent grounds for vacatur.
Wearable cardiac monitoring patents are active litigation flashpoints
Three patents covering discordance monitoring and arrhythmia tracking methods remain in live dispute. Any organisation developing heart rate monitoring, ECG, or arrhythmia detection features in wearables — including smartwatches, fitness bands, and medical-grade devices — should monitor the ITC remand outcome closely as a bellwether for enforcement posture.
Apple v International — key questions answered
The Federal Circuit vacated the International Trade Commission’s determination and remanded the case for further proceedings. The order, issued on 7 March 2025, nullifies the ITC’s prior ruling on three patents — US9572499B2, US10638941B2, and US10595731B2 — covering discordance monitoring and arrhythmia tracking. Neither party secured a final merits victory; the ITC must now reconsider the matter.
Three patents were involved: US9572499B2, US10638941B2, and US10595731B2. They cover discordance monitoring and methods and systems for arrhythmia tracking and scoring — technologies relevant to cardiac health monitoring in wearable devices such as smartwatches. The patents appear to form a related family based on their application numbers.
Vacatur means the ITC’s original determination is legally nullified — it carries no binding effect. Remand means the case is sent back to the ITC to reconsider the issue under whatever corrected legal standard the Federal Circuit prescribed. Unlike a reversal, the Federal Circuit did not substitute its own final judgment; the ITC must now re-examine the three cardiac monitoring patents from a corrected analytical starting point.
The appeal ran for 735 days, from filing on 3 March 2023 to the Federal Circuit’s order on 7 March 2025. This duration is consistent with a substantive merits review at the Federal Circuit rather than a procedural dismissal, suggesting the court engaged with the legal arguments around the cardiac monitoring patents in depth before issuing its vacatur.
The case returns to the International Trade Commission, which must reconsider its determination on the three cardiac monitoring patents — US9572499B2, US10638941B2, and US10595731B2 — consistent with the Federal Circuit’s guidance. The ITC’s remand proceedings could result in a new determination favourable to either Apple or the patent holder. Any exclusion order or finding from the original ITC decision cannot be relied upon while the remand is pending.
PatSnap Eureka searches patents and litigation data to answer instantly.